This company seems to have been delisted
Reason: Filed for chapter 11 bankruptcy
Last recorded trade on: March 12, 2024
Source: https://www.fiercebiotech.com/biotech/athersys-files-bankruptcy-sells-assets-healios-wake-roke-cell-therapys-struggles
Reason: Filed for chapter 11 bankruptcy
Last recorded trade on: March 12, 2024
Source: https://www.fiercebiotech.com/biotech/athersys-files-bankruptcy-sells-assets-healios-wake-roke-cell-therapys-struggles
Athersys
ATHX
NZ$0.02265
Share price
-33.50%
Change (1 day)
-98.91%
Change (1 year)
Categories
Athersys (ATHX) - Net assets
Net assets on the balance sheet as of September 2023 : -NZ$61.07 Million
According to Athersys's latest financial reports the company has -NZ$61.07 Million in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Athersys - Net assets on balance sheet (from 2005 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $-NZ$37.57 Million | -256.76% |
| 2021-12-31 | $NZ$23.96 M | -44.86% |
| 2020-12-31 | $NZ$43.46 M | 25.79% |
| 2019-12-31 | $NZ$34.55 M | -46.24% |
| 2018-12-31 | $NZ$64.27 M | 95.29% |
| 2017-12-31 | $NZ$32.91 M | 103.91% |
| 2016-12-31 | $NZ$16.14 M | -43.99% |
| 2015-12-31 | $NZ$28.81 M | 8.06% |
| 2014-12-31 | $NZ$26.66 M | 10.56% |
| 2013-12-31 | $NZ$24.12 M | -2% |
| 2012-12-31 | $NZ$24.61 M | 163.21% |
| 2011-12-31 | $NZ$9.35 M | -19.89% |
| 2010-12-31 | $NZ$11.67 M | -55.28% |
| 2009-12-31 | $NZ$26.09 M | -52.01% |
| 2008-12-31 | $NZ$54.38 M | -12.53% |
| 2007-12-31 | $NZ$62.18 M | -8572981.3% |
| 2006-12-31 | $-NZ$0.01 Million | -149.58% |
| 2005-12-31 | $NZ$0 M | 4.4% |
| 2004-12-31 | $NZ$0 M | -99.99% |
| 2003-12-31 | $NZ$22.99 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | NZ$10.41 B | -17,154.54% | 🇺🇸 USA |
 Pfizer PFE | NZ$152.07 B | -249,136.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$29.27 B | -48,040.65% | 🇺🇸 USA |
 Moderna
MRNA | NZ$16.88 B | -27,757.65% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$131.05 B | -214,714.64% | 🇺🇸 USA |
 United States Lime & Minerals USLM | NZ$0.89 B | -1,562.31% | 🇺🇸 USA |
 Merck MRK | NZ$81.21 B | -133,085.30% | 🇺🇸 USA |
 Sanofi SNY | NZ$135.09 B | -221,317.20% | 🇫🇷 France |